Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sensei Biotherapeutics, Inc.

0.4030
+0.02306.05%
Post-market: 0.41500.0120+2.98%16:15 EDT
Volume:101.94K
Turnover:38.54K
Market Cap:10.16M
PE:-0.34
High:0.4053
Open:0.4053
Low:0.3601
Close:0.3800
Loading ...

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

GlobeNewswire
·
02 Apr

Sensei Biotherapeutics (SNSE) Gets a Buy from Oppenheimer

TIPRANKS
·
30 Mar

Sensei Biotherapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
28 Mar

Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating

MT Newswires Live
·
28 Mar

Sensei Biotherapeutics Inc : >: Oppenheimer Raises Target Price to $4 From $3.5

THOMSON REUTERS
·
28 Mar

BRIEF-Sensei Biotherapeutics Inc Cash Runway Into Q2 Of 2026

Reuters
·
28 Mar

Sensei Biotherapeutics Inc -Cash Runway Into Q2 of 2026

THOMSON REUTERS
·
28 Mar

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

GlobeNewswire
·
28 Mar

Sensei Biotherapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

Buy Rating for Sensei Biotherapeutics Driven by Promising Solnerstotug Trial Results and Strong Financial Projections

TIPRANKS
·
28 Mar

Sensei Biotherapeutics Reports Promising Phase 1/2 Trial Results

TIPRANKS
·
28 Mar

BRIEF-Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors

Reuters
·
28 Mar

Sensei Biotherapeutics announces initial results from solnerstotug trial portion

TIPRANKS
·
28 Mar

Sensei Biotherapeutics Inc: Early Data Suggest Solnerstotug May Provide a Meaningful Clinical Benefit in Select Tumor Types

THOMSON REUTERS
·
28 Mar

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in Pd-(L)1 Resistant Tumors

THOMSON REUTERS
·
28 Mar

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

GlobeNewswire
·
28 Mar

Sensei Biotherapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
24 Feb

What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock

Zacks
·
07 Feb

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

GlobeNewswire
·
04 Feb

Sensei Biotherapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan